Inhibition of PI3K in HER2-positive breast cancer, on the other hand, results in compensatory activation of ERK signaling by HER family receptors, which can be avoided by coadministration of MEK inhibitors or anti-HER2 drugs [127]. Here, ERBB2 is linked to breast cancer.